Abstract
MG53 is a member of the TRIM-family protein that acts as a key component of the cell membrane repair machinery. MG53 is also an E3-ligase that ubiquinates insulin receptor substrate-1 and controls insulin signaling in skeletal muscle cells. Since its discovery in 2009, research efforts have been devoted to translate this basic discovery into clinical applications in human degenerative and metabolic diseases. This review article highlights the dual function of MG53 in cell membrane repair and insulin signaling, the mechanism that underlies the control of MG53 function, and the therapeutic value of targeting MG53 function in regenerative medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 414-423 |
| Number of pages | 10 |
| Journal | BMB reports |
| Volume | 49 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2016 |
Bibliographical note
Funding Information:Grant supports are provided to J.M. by the NIH (HL69000, AR061385 and DK106394), to T.T. by NSFC (81401155), and to Y.G.K. by the KHIDI (HI14C1234). J.M. is a Founder of TRIM-edicine, Inc., a biotechnology company developing rhMG53 as a therapeutic protein.
Publisher Copyright:
© 2016 by the The Korean Society for Biochemistry and Molecular Biology.
Keywords
- E3 ligase
- Insulin resistance
- MG53
- Membrane repair
- Muscular dystrophy
- TRIM72
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
